Ikena Other Liab vs Total Current Liabilities Analysis
IKNA Stock | USD 1.29 0.06 4.44% |
Ikena Oncology financial indicator trend analysis is infinitely more than just investigating Ikena Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ikena Oncology is a good investment. Please check the relationship between Ikena Oncology Other Liab and its Total Current Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.
Other Liab vs Total Current Liabilities
Other Liab vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ikena Oncology Other Liab account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.
The correlation between Ikena Oncology's Other Liab and Total Current Liabilities is 0.76. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Ikena Oncology, assuming nothing else is changed. The correlation between historical values of Ikena Oncology's Other Liab and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Ikena Oncology are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Other Liab i.e., Ikena Oncology's Other Liab and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.76 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Liab
Total Current Liabilities
Total Current Liabilities is an item on Ikena Oncology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ikena Oncology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Ikena Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ikena Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.At present, Ikena Oncology's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.86, whereas Selling General Administrative is forecasted to decline to about 17.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 65.1M | 86.5M | 83.6M | 70.7M | Cost Of Revenue | 47.1M | 2.0M | 1.0M | 969K |
Ikena Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Ikena Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ikena Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Current Liab | 121K | 5.4M | 5.9M | 8.3M | 8.6M | 5.2M | |
Total Current Liabilities | 24.3M | 28.3M | 27.2M | 21.5M | 14.2M | 21.9M | |
Net Tangible Assets | (61.5M) | (101.0M) | 207.9M | 147.0M | 169.0M | 177.5M | |
Retained Earnings | (67.1M) | (111.3M) | (145.5M) | (214.2M) | (282.4M) | (268.3M) | |
Accounts Payable | 935K | 2.1M | 2.4M | 2.1M | 2.1M | 2.2M | |
Other Current Assets | 1.3M | 1.6M | 629K | 964K | 3.2M | 3.4M | |
Total Current Assets | 85.2M | 166.0M | 236.5M | 160.0M | 178.7M | 155.2M | |
Property Plant Equipment | 769K | 1.6M | 2.4M | 3.2M | 3.7M | 1.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Ikena Stock analysis
When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Ikena Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.63) | Revenue Per Share 0.219 | Quarterly Revenue Growth (0.88) | Return On Assets (0.26) | Return On Equity (0.43) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.